Zhejiang Huahai Pharmaceutical (600521.SH): Linagliptin Metformin Tablets () Obtains Drug Registration Certificate.

Zhejiang Huahai Pharmaceutical (600521.SH) announced that the company recently received the "Drug Registration Certificate" for the approval and issuance of linagliptin metformin tablets (II) from the National Medical Products Administration (NMPA). The approved product is mainly used for type 2 diabetes adult patients who are suitable for treatment with linagliptin and metformin, to improve the blood sugar control level of these patients.